Medication

Tirzepatide: prices by provider and plan

A dual GIP/GLP-1 receptor agonist available as FDA-approved branded products (Zepbound, Mounjaro) and, separately, as compounded preparations that are not FDA-approved. Below: every priced offering in our dataset, sorted by monthly equivalent, with the evidence status of each figure. This page describes pricing and disclosure — it is not dosing or treatment advice.

All priced offerings (35)

13 additional rows exist in the dataset without a usable price and are excluded from the table rather than shown with a guessed figure.

Branded vs compounded: not the same product

This table mixes FDA-approved branded products (10 rows) with compounded preparations (25 rows). Compounded tirzepatide is not FDA-approved: the FDA does not review compounded drugs for safety, effectiveness, or quality before marketing, and the price difference between the two columns reflects that regulatory difference, not a discount on the same product. The branded rows are the only ones describing an FDA-approved product.

Providers offering tirzepatide

• NexLife — States use of U.S.-licensed 503A compounding pharmacies; specific pharmacy not yet named to us
• Hims & Hers — dispensing pharmacy not publicly disclosed
• Mochi Health — dispensing pharmacy not publicly disclosed
• Henry Meds — dispensing pharmacy not publicly disclosed
• Found — dispensing pharmacy not publicly disclosed
• PlushCare — dispensing pharmacy not publicly disclosed
• Noom Med — dispensing pharmacy not publicly disclosed
• Eden — dispensing pharmacy not publicly disclosed
• Shed — dispensing pharmacy not publicly disclosed
• Enhance.MD — dispensing pharmacy not publicly disclosed
• Oak Longevity — dispensing pharmacy not publicly disclosed
• TrimRx — dispensing pharmacy not publicly disclosed
• MEDVi — dispensing pharmacy not publicly disclosed
• bmiMD — dispensing pharmacy not publicly disclosed
• Zappy Health — dispensing pharmacy not publicly disclosed
• Calibrate — dispensing pharmacy not publicly disclosed
• Form Health — dispensing pharmacy not publicly disclosed
• IVIM Health — dispensing pharmacy not publicly disclosed

Related research in the casebook

• SURMOUNT-1 — Tirzepatide in adults with obesity or overweight
• SURMOUNT-3 — Tirzepatide after intensive lifestyle intervention
• SURMOUNT-4 — Continued tirzepatide versus withdrawal for weight maintenance
• SURMOUNT-5 — Tirzepatide versus semaglutide, head to head
• SURMOUNT-OSA — Tirzepatide in obstructive sleep apnoea with obesity
• SUMMIT — Tirzepatide in heart failure with preserved ejection fraction and obesity
• SURMOUNT-1, three-year prediabetes analysis — Progression to type 2 diabetes
• SURPASS-2 — Tirzepatide versus semaglutide in type 2 diabetes
• Body-composition analyses — Lean mass change during tirzepatide treatment
• Renal outcome analyses — Kidney endpoints with tirzepatide
• SYNERGY-NASH — Tirzepatide in MASH with fibrosis
• PCOS evidence base — Tirzepatide in polycystic ovary syndrome
• SURPASS-CVOT — Cardiovascular outcomes with tirzepatide
• SURPASS programme — Glycaemic outcomes with tirzepatide
• SYNERGY-NASH — Tirzepatide for MASH with liver fibrosis

What this page can't tell you

Whether any of these prices is current (capture dates are shown; prices in this market change monthly), what dose a listed plan actually covers unless stated, whether a compounded preparation's quality matches any standard, and whether this medication is appropriate for you — that last one is a question for a licensed clinician, full stop. What we can tell you is which claims have sources and which don't: as of this build, no tirzepatide price here has been independently verified by us — see the pricing verification methodologyfor what verification would require.